- Home
- SES vs GLUE Comparison
SES vs GLUE Comparison
Compare SES & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- GLUE
- Stock Information
- Founded
- SES 2012
- GLUE 2019
- Country
- SES United States
- GLUE United States
- Employees
- SES N/A
- GLUE N/A
- Industry
- SES Auto Parts:O.E.M.
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- GLUE Health Care
- Exchange
- SES Nasdaq
- GLUE Nasdaq
- Market Cap
- SES 384.0M
- GLUE 351.2M
- IPO Year
- SES N/A
- GLUE 2021
- Fundamental
- Price
- SES $1.12
- GLUE $4.80
- Analyst Decision
- SES Hold
- GLUE Buy
- Analyst Count
- SES 3
- GLUE 2
- Target Price
- SES $1.50
- GLUE $13.50
- AVG Volume (30 Days)
- SES 5.6M
- GLUE 369.2K
- Earning Date
- SES 08-04-2025
- GLUE 08-07-2025
- Dividend Yield
- SES N/A
- GLUE N/A
- EPS Growth
- SES N/A
- GLUE N/A
- EPS
- SES N/A
- GLUE 0.29
- Revenue
- SES $11,360,000.00
- GLUE $177,986,000.00
- Revenue This Year
- SES $883.92
- GLUE $83.76
- Revenue Next Year
- SES $159.98
- GLUE N/A
- P/E Ratio
- SES N/A
- GLUE $16.32
- Revenue Growth
- SES N/A
- GLUE 2990.57
- 52 Week Low
- SES $0.20
- GLUE $3.50
- 52 Week High
- SES $2.53
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- SES 51.03
- GLUE 51.69
- Support Level
- SES $1.09
- GLUE $4.54
- Resistance Level
- SES $1.22
- GLUE $4.93
- Average True Range (ATR)
- SES 0.07
- GLUE 0.21
- MACD
- SES -0.00
- GLUE 0.06
- Stochastic Oscillator
- SES 55.32
- GLUE 81.43
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.